Aquestive Therapeutics, Inc. AQST Royalty receivable
Royalty receivable at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:CumulativeRoyaltyReceivable.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty receivable?
- Aquestive Therapeutics, Inc. (AQST) reported royalty receivable of $2M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s royalty receivable changed year-over-year?
- Aquestive Therapeutics, Inc.'s royalty receivable decreased by 33.3% year-over-year, from $3M to $2M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty receivable?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s royalty receivable has grown at a -22.2% compound annual growth rate (CAGR), from $7M to $2M.
- What does royalty receivable mean?
- This represents the total amount of royalty income earned from licensing intellectual property or commercial partnerships that has been recognized as revenue but not yet collected in cash. It serves as an indicator of the company's ability to monetize its proprietary technology through third-party commercialization. High balances may indicate a reliance on partner payment cycles.